» Articles » PMID: 32945367

Propofol Protects Against Oxygen/glucose Deprivation‑induced Cell Injury Via Gap Junction Inhibition in Astrocytes

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2020 Sep 18
PMID 32945367
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Stroke is one of the leading causes of mortality and disability worldwide with limited clinical therapies available. The present study isolated primary astrocytes from the brains of rats and treated them with oxygen‑glucose deprivation and re‑oxygenation (OGD/R) to mimic hypoxia/reperfusion (H/R) injury in vitro to investigate stroke. It was revealed that propofol (2,6‑diisopropylphenol), an intravenous sedative and anesthetic agent, protected against oxygen/glucose‑deprivation (OGD) and induced cell injury. Furthermore, propofol exerted a protective effect by inhibiting gap junction function, which was also revealed to promote cell death in astrocytes. The present study further identified that propofol suppressed gap junction function by downregulating the protein expression levels of connexin43 (Cx43), which is one of the most essential components of gap junctions in astrocytes. In addition, when the expression levels of Cx43 were downregulated using small interfering RNA, OGD/R‑induced cell death was decreased. Conversely, cell death was enhanced when Cx43 was overexpressed, which was reversed following propofol treatment. In summary, propofol protects against OGD‑induced injury in astrocytes by decreasing the protein expression levels of Cx43 and suppressing gap junction function. The present study improved our understanding of how propofol protects astrocytes from OGD/R‑induced injury.

Citing Articles

Research progress of propofol in alleviating cerebral ischemia/reperfusion injury.

Zheng H, Xiao X, Han Y, Wang P, Zang L, Wang L Pharmacol Rep. 2024; 76(5):962-980.

PMID: 38954373 DOI: 10.1007/s43440-024-00620-6.


The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics.

VanderZwaag J, Halvorson T, Dolhan K, Simoncicova E, Ben-Azu B, Tremblay M Neurochem Res. 2022; 48(4):1129-1166.

PMID: 36327017 DOI: 10.1007/s11064-022-03772-0.


Focus on the role of mitochondria in NLRP3 inflammasome activation: A prospective target for the treatment of ischemic stroke (Review).

Zhang X, Zeng W, Zhang Y, Yu Q, Zeng M, Gan J Int J Mol Med. 2022; 49(6).

PMID: 35419616 PMC: 9015651. DOI: 10.3892/ijmm.2022.5130.

References
1.
Majid A . Neuroprotection in stroke: past, present, and future. ISRN Neurol. 2014; 2014:515716. PMC: 3918861. DOI: 10.1155/2014/515716. View

2.
Deng Z, Liao J, Zhang J, Liang C, Song C, Han M . Inhibition of the connexin 43 elevation may be involved in the neuroprotective activity of leptin against brain ischemic injury. Cell Mol Neurobiol. 2014; 34(6):871-9. PMC: 11488862. DOI: 10.1007/s10571-014-0066-5. View

3.
Frantseva M, Kokarovtseva L, Naus C, Carlen P, MacFabe D, Perez Velazquez J . Specific gap junctions enhance the neuronal vulnerability to brain traumatic injury. J Neurosci. 2002; 22(3):644-53. PMC: 6758478. View

4.
Li C, Li X, Liu S, Qu W, Wang W, Tian D . Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen-glucose deprivation and reoxygenation. Neurochem Int. 2015; 83-84:9-18. DOI: 10.1016/j.neuint.2015.03.001. View

5.
Harris A . Connexin channel permeability to cytoplasmic molecules. Prog Biophys Mol Biol. 2007; 94(1-2):120-43. PMC: 1995164. DOI: 10.1016/j.pbiomolbio.2007.03.011. View